Brain metastases - Pipeline Insight, 2022

Brain metastases - Pipeline Insight, 2022

DelveInsight’s, “Brain Metastases – Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Brain Metastases pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Brain Metastases Understanding

Brain Metastases: Overview

Brain metastases are the most common intracranial tumor in adults and may affect up to 200,000 patients per year. The three most common primary malignancies that metastasize to the brain are lung, breast, and melanoma. Additional cancers with brain metastases include renal cell, colorectal cancer, and gynecologic cancers. Signs and symptoms caused by brain metastases can vary based on the location, size and rate of growth of the metastatic tumors. About one third of patients with another type of cancer will develop one or more metastatic brain tumors. The risk for metastatic brain tumors begins to increase after age 45 and is highest in those over 65. Signs and symptoms of brain metastases include: Headache, sometimes with vomiting or nausea, mental changes, such as increasing memory problems, Seizures, and Weakness or numbness on one side of the body. Brain metastasis diagnosis is suspected through thorough physical examination and history. Brain metastasis can be diagnosed utilizing the following tests: Computed Axial Tomography, Magnetic Resonance Imaging and others. Treatment varies with the size and type of the tumor, the primary site of the malignancy, its extent both locally and in the rest of the body (staging), the general health of the individual and presence of other significant medical problems.

""Brain Metastases - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Brain Metastases pipeline landscape is provided which includes the disease overview and Brain Metastases treatment guidelines. The assessment part of the report embraces, in depth Brain Metastases commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain Metastases collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Brain Metastases R&D. The therapies under development are focused on novel approaches to treat/improve Brain Metastases.

Brain Metastases Emerging Drugs Chapters

This segment of the Brain Metastases report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Brain Metastases Emerging Drugs

Icotinib: Betta Pharmaceuticals

Icotinib is orally bioavailable highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) which binds reversibly to the ATP binding site of the EGFR protein, and preventing completion of the signal transduction cascade. The drug is currently being evaluated in Phase III stage of development to Determine the Efficiency of Icotinib Combined With Radiation Therapy Early Intervention or Late Intervention For NSCLC Patients With Brain Metastases.

HBI-8000: HUYA Bioscience International

HBI-8000 is a Class I selective oral HDACi with immunomodulatory effects including enhanced cell-mediated toxicity, enhanced tumor infiltration by cytotoxic T-cells and reduced tumor infiltration by T-regulatory cells. Phase III clinical trials are being evaluated for the treatment of patients with progressive brain metastasis.

ANG1005: Angiochem

ANG1005 is a novel targeted taxane derivative that is the first oncology product to leverage Angiochem’s technology platform to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 is an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain. Currently, the drug is being evaluated in Phase III stage of Clinical trial evaluation for the treatment of Brain metastases.

AZD3759: Alpha BioPharma

Alpha Bio is conducting multi-center Phase II/III clinical study of AZD3759, a TKI for EGFR mutation-positive cases of non-small cell lung cancer with CNS metastasis particularly brain metastasis.

Further product details are provided in the report……..

Brain Metastases: Therapeutic Assessment

This segment of the report provides insights about the different Brain Metastases drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Brain Metastases

There are approx. 50+ key companies which are developing the therapies for Brain Metastases. The companies which have their Brain Metastases drug candidates in the most advanced stage, i.e. Phase III include,Betta Pharmaceuticals.


DelveInsight’s report covers around 50+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Brain Metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as






Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody



Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Brain Metastases: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Brain Metastases therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Brain Metastases drugs.

Brain Metastases Report Insights

Brain Metastases Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Brain Metastases Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Brain Metastases drugs?

How many Brain Metastases drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Brain Metastases?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Brain Metastases therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Brain Metastases and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

•Betta Pharmaceuticals

•HUYA Bioscience International


•Alpha BioPharma


•EpicentRx, Inc.

•Medolution Ltd.

•Blue Earth Diagnostics

•Bristol-Myers Squibb

•Novartis Pharmaceuticals

Key Products





•BMX 001



•18F fluciclovine



Executive Summary
Brain Metastases: Overview
Mechanism of Action
Signs and Symptoms
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Brain Metastases – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Brain Metastases companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Brain Metastases Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Icotinib: Betta Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
AZD3759: Alpha BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
BMX-001: BioMimetix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Brain Metastases Key Companies
Brain Metastases Key Products
Brain Metastases- Unmet Needs
Brain Metastases- Market Drivers and Barriers
Brain Metastases- Future Perspectives and Conclusion
Brain Metastases Analyst Views
Brain Metastases Key Companies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings